期刊文献+

卵巢癌的筛查和早期诊断 被引量:14

Ovarian cancer screening and early diagnosis
原文传递
导出
摘要 卵巢癌是目前妇科肿瘤中病死率最高的恶性肿瘤,若能做到早期诊断,则将大大提高其5年生存率。而在世界范围内仍然缺乏有效的筛查手段,妇科检查、经阴道超声检查和血清学CA125的联合检查可以起到一定的判别作用。蛋白质组学技术以及新的肿瘤标志物,可能为未来卵巢癌的筛查提供更为敏感的方法。 The ovarian cancer has the highest mortali- ty in gynecology cancers, and the early detection will improve the 5 years of survival rate. But there are still no effective methods to screen for ovarian caners. Gynecologist can only use combination of the pelvic examination, transvaginal ultrasound and CA125 as the methods to diagnosis pelvic mass. The proteomics and the new tumor markers will offer more sensitive and specific screening for the ovarian cancer in future.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2012年第3期166-169,共4页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢癌 筛查 早期诊断 经阴道超声检查 ovarian cancer screening early detec- tion transvaginal ultrasound
  • 相关文献

参考文献31

  • 1Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem[J]. Best Pract Res Clin Obstet Gynaecol,2006,20 ( 2 ) : 207-225.
  • 2Badgwell D, Bast RC Jr. Early detection of ovarian cancer [ J ]. Dis Markers, 2007,23(5-6) :397-410.
  • 3Cragun JM. Screening for ovarian cancer [ J ]. Cancer Control, 2011,18( 1 ) :16-21.
  • 4Myers ER,. Bastian LA, Havrilesky LJ. Management of adnexal mass[ J ]. Evid Rep Technol Assess ( Full Rep),2006, (130) : 1-145.
  • 5Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory [ J ]. Ann Clin Biochem,2011,48 ( Pt 4) :295-299.
  • 6Sjsvall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases[J]. Gynecol Oncol,2002,85( 1 ) :175-178.
  • 7Skates SJ, Horick N, Yu Y. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions [ J ]. J Clin Oncol, 2004,22(20):4059-4066.
  • 8Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer Prev Res (Phila), 2011,4 ( 9 ) : 1356- 1359.
  • 9Xu Y, Gaudette DC, Boynton JD. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients [ J]. Clin Cancer Res, 1995, 1 (10) : 1223-1232.
  • 10Xu Y, Shen Z, Wiper DW. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers[J]. JAMA, 1998,280(8 ) :719-723.

二级参考文献25

  • 1顾平(综述),盛世乐(审校),黄钢(审校).肿瘤标志物在卵巢癌中的应用[J].国际肿瘤学杂志,2007,34(3):226-228. 被引量:6
  • 2Sica GL,Choi IH,Zhu G,et al.B7-H4,a molecule of the B7family,negatively regulates T cell immunity.Immunity,2003,18:849-861.
  • 3Choi IH,Zhu G,Sica GL,et al.G enomic organization and expression analysis of B7-H4,an immune inhibitory molecule of the B7 family.J Immunol,2003,171:4650-4654.
  • 4Bignotti E,Tassi RA,Calza S,et al.Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas:identification of novel molecular biomarkers for early diagnosis and therapy.Gynecol Oncol,2006,103:405-416.
  • 5Salceda S,Tang T,Kmet M,et al.The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.Exp Cell Res,2005,306:128-141.
  • 6Tringler B,Liu W,Corral L,et al.B7-H4 overexpression in ovarian tumors Gyneeol Oncol,2006,100:44-52.
  • 7Simon I,Katsaros D,Rigault de la Longrais I,et al.B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.Gynecol Oncol,2007,106:334-341.
  • 8Kryczek I,Wei S,Zhu G,et al.Relationship between B7-H4,regulatory T cells,and patient outcome in human ovarian carcinoma.Cancer Res,2007,67:8900-8905.
  • 9Bast RC, Feeney M, Lazarus Het al. Reactivity of a monoclonal anti- body with human ovarian carcinoma [ J] . J Clin Invest, 1981, 68: 1331.
  • 10Berek JS, Bast RC. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection [J] . Cancer, 1995, 76:2092.

共引文献31

同被引文献139

  • 1吴鸣,沈铿,郎景和,黄荣丽,黄惠芳,潘凌亚.Ⅲ期卵巢上皮性癌临床和预后因素分析[J].中华医学杂志,2005,85(20):1406-1409. 被引量:16
  • 2李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 3崔恒.卵巢癌的诊治及其研究策略[J].中国妇产科临床杂志,2006,7(5):323-326. 被引量:24
  • 4刘丽,丁辉,潘迎,邱立苹,陶旻枫,王连英.北京市1993~2004年住院妇科肿瘤疾病谱分析[J].中国卫生统计,2007,24(2):221-221. 被引量:10
  • 5周琦,李莉,李庭房,等.腹腔镜技术在卵巢癌再分期手术中的应用(附22例报道.中国内镜杂志,2010,16(8):870-872.
  • 6华嘉增,朱丽萍.现代妇女保健学[M].上海:复旦大学出版社,2011:503.
  • 7Ivanov S, Batashki I. Five years survival in patients with endometri- oid ovarian cancer versus patients with serous ovarian cancer. Akush Ginekol (Sofiia) . 2008.47 ( 5 ) :9 - 11.
  • 8谢敏,李艺,崔恒.复发性卵巢癌的手术治疗,2012,28(5):330-334.
  • 9李艺,张芸娜,马或,等.原发性卵巢粘液性癌的临床特征分析,2012,21(2):89-93.
  • 10Bell J, Brady MF, Young RC, et al . Randomized phase 11I trial of three versus six cycles of adjuvant carbopatin and paclitaxel in early stage epithelial ovarian carcinoma : a Gynecologic Oncology Group study . Gynecol Oncol ,2006,102 ( 3 ) :432 - 439.

引证文献14

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部